<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00907933</url>
  </required_header>
  <id_info>
    <org_study_id>111610</org_study_id>
    <nct_id>NCT00907933</nct_id>
  </id_info>
  <brief_title>Intranasal SB-705498 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study in Healthy Volunteers to Examine the Safety, Tolerability and Pharmacokinetics of a) Single, Ascending and b) Twice-daily Repeat Doses of Intranasal SB-705498</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a First Time in Human (FTIH) study to investigate the safety, tolerability and
      pharmacokinetics (PK) of a) single, escalating and b) twice-daily 14 days repeat doses of
      intranasal SB-705498 in healthy volunteers (HVT). The safety and tolerability of single
      intranasal 498 dosing will be assessed and established before initiating the evaluation of
      repeat intranasal 498 dosing.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 10, 2008</start_date>
  <completion_date type="Actual">February 11, 2009</completion_date>
  <primary_completion_date type="Actual">February 11, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability (Electrocardiogram, vital signs, lab tests, AEs and nasal tolerability</measure>
    <time_frame>Various</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Single dose derived pharmacokinetics (Cmax, tmax, AUC(0-4) and AUC(o-infinity); Part 2: Repeat dose derived pharmacokinetics (Cmax, tmax, AUC(0-4) and AUC(o-infinity)</measure>
    <time_frame>Part 1: Various timepoints through the day; Part 2: Various timepoints over 14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Rhinitis</condition>
  <arm_group>
    <arm_group_label>Part 1 - Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HVTs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>HVTs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HVTs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HVTs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HVTs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Arm 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HVTs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Arm 6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>HVTs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HVTs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HVTs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-705498</intervention_name>
    <description>0.5mg intranasal SB-705498</description>
    <arm_group_label>Part 1 - Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-705498</intervention_name>
    <description>1.5mg intranasal SB-705498</description>
    <arm_group_label>Part 1 - Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-705498</intervention_name>
    <description>3mg intranasal SB-705498</description>
    <arm_group_label>Part 1 - Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-705498</intervention_name>
    <description>6mg intranasal SB-705498</description>
    <arm_group_label>Part 1 - Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-705498</intervention_name>
    <description>12mg intranasal SB-705498</description>
    <arm_group_label>Part 1 - Arm 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo '498</description>
    <arm_group_label>Part 1 - Arm 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-705498</intervention_name>
    <description>6mg intranasal SB-705498 for 14 days bid</description>
    <arm_group_label>Part 2 - Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-705498</intervention_name>
    <description>12mg intranasal SB-705498 14 days bid</description>
    <arm_group_label>Part 2 - Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Part 2 - Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, as determined by a responsible physician, based on a medical evaluation
             including medical history, physical examination, laboratory tests and cardiac
             monitoring.

          -  Male or female between 18 and 60 years of age inclusive.

          -  A female subject is eligible to participate if she is of:

          -  Non-childbearing potential defined as females with documented tubal occlusion,
             bilateral salpingectomy, bilateral oophorectomy or hysterectomy; or postmenopausal
             defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample
             with simultaneous FSH &gt; 40 MlU/ml and estradiol &lt; 40 pg/ml (&lt;140 pmol/L) is
             confirmatory]. Females on hormone replacement therapy (HRT) and whose menopausal
             status is in doubt will be required to use one of the contraception methods in the
             protocol if they wish to continue their HRT during the study. Otherwise, they must
             discontinue HRT to allow confirmation of post-menopausal status prior to study
             enrolment. For most forms of HRT, at least 2-4 weeks should elapse between the
             cessation of therapy and the blood draw; this interval depends on the type and dosage
             of HRT. Following confirmation of their post-menopausal status, they can resume use of
             HRT during the study without use of a contraceptive method.

          -  Child-bearing potential and agrees to use one of the contraception methods listed in
             the protocol. Female subjects willing to participate in the study must agree to use
             contraception from the screening visit until 15 days post-last treatment
             administration.

          -  Male subjects must agree to use one of the contraception methods listed in the
             protocol. For male subjects willing to participate in the study this criterion must be
             followed from the time of the screening visit until 15 days post-last treatment
             administration.

          -  Non-smoker for at least 6 months with a pack history less than or equal to 5 pack
             years (Pack years = (No. of cigarettes smoked/day/20) x No. of years smoked).

          -  Body weight greater than or equal to 50 kg and body mass index (BMI) within the range
             19 - 29.9 kg/m2 (inclusive).

          -  Normal assessment of vital signs and 12-lead ECG at screening. A subject may be
             included in the study if any abnormality is deemed not clinically significant by the
             Investigator.

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form.

          -  Available to complete all the required study measurements.

        Exclusion Criteria:

          -  Past medical history of rhinitis, including allergic, non-allergic rhinitis and
             rhinosinusitis. Subjects with recent upper respiratory tract infections (URTIs) will
             be allowed in the study only if their nasal symptoms have been completely resolved for
             more than 3 weeks prior to screening.

          -  Nasal conditions likely to affect the outcome of the study, i.e. nasal septal
             perforation, nasal polyps, other nasal malformations.

          -  History of frequent nosebleeds.

          -  A history of gastro-intestinal, hepatic, renal or other condition known to interfere
             with the absorption, distribution, metabolism or excretion of drugs.

          -  History of regular alcohol consumption within 6 months of the study defined as: an
             average weekly intake of greater than 21 units or an average daily intake of greater
             than 3 units (males), or defined as an average weekly intake of greater than 14 units
             or an average daily intake of greater than 2 units (females). One unit is equivalent
             to a half-pint (220mL) of beer or 1 (25ml) measure of spirits or 1 glass (125ml) of
             wine.

          -  Positive pre-study drug/alcohol/smoking screen. A minimum list of drugs that will be
             screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids,
             benzodiazepines and methadone.

          -  Positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result
             within 3 months of screening.

          -  A positive test for human immunodeficiency virus (HIV) antibody.

          -  Exposure to more than four new chemical entities within 6 months prior to the start of
             the study.

          -  Participation in a clinical trial with a new molecule entity or any other clinical
             trial within 3 months of the start of the study.

          -  Use of prescription or non-prescription drugs, as well as of vitamins, herbal and
             dietary supplements (including St John's Wort) within 7 days prior to the first dose
             of study medication, unless in the opinion of the Investigator and GSK Medical Monitor
             the medication will not interfere with the study procedures or compromise subject
             safety.

          -  History of drug or other allergy that, in the opinion of the Investigator or GSK
             Medical Monitor, contraindicates participation in this study.

          -  Donation of blood or blood products in excess of 500mL within a 56 day period prior
             the start of this study.

          -  Pregnant females as determined by positive serum or urine beta-human chorionic
             gonadatrophin (beta-hCG) test at screening or prior to dosing.

          -  Lactating females.

          -  Unwillingness or inability to follow the procedures outlined in the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/111610?search=study&amp;search_terms=111610#rs</url>
    <description>Results for study 111610 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2009</study_first_submitted>
  <study_first_submitted_qc>May 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2009</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>111610</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111610</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111610</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111610</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111610</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111610</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111610</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

